ARTBIO – a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs) – recently announced the closing of an oversubscribed and upsized $90 million Series A financing co-led by Third Rock Ventures and an undisclosed healthcare fund. And seed lead investors F-Prime Capital and Omega Funds participated substantially. The company’s prior seed investment round of $23 million was announced in June 2023.
Along with the Series A closing, ARTBIO appointed industry veterans Philippe Dasse, Pharm.D., as Chief Technical Officer and Daniel Rossetto as Head and Senior Vice President of Supply Chain and External Manufacturing. In these roles, Philippe and Daniel will lead the development and expansion of ARTBIO’s distributed manufacturing network in support of the company’s clinical pipeline.
The appointments of Philippe and Daniel to the management team will strengthen the company’s capabilities during this critical stage. In Philippe’s role as Chief Technical Officer, he will lead the development of ARTBIO’s proprietary AlphaDirect technology and establishment of the company’s distributed manufacturing network. And Philippe was most recently Head of Technical Operations for Radioligand Therapies at Novartis Oncology. Philippe was also the first employee of Advanced Accelerator Applications in 2002, a company acquired by Novartis in 2018, and covered increasing responsibilities to lead all technical operations before his departure.
In Daniel’s role as Head and Senior Vice President of Supply Chain and External Manufacturing, he will lead efforts to enhance the company’s supply chain logistics and manufacturing partnerships to ensure the seamless distribution of ARTs. And Daniel has a long career in pharmaceutical manufacturing and was most recently the Global Head of Supply Chain at Advanced Accelerator Applications, Novartis. In this role, Daniel managed a diverse team to scale up a high-speed and agile internal and external supply network to deliver the clinical and commercial RLT portfolio which included PLUVICTO to prostate cancer patients.
KEY QUOTES:
“We are thrilled to have the support of our new and existing investors, including Third Rock Ventures, F-Prime Capital and Omega Funds. These groups bring significant expertise in company scale-up and pipeline development that will be invaluable as we continue to progress our programs and pipeline. Next year will be an important one for the company as we advance our lead program, AB001, and our entire pipeline, while further developing a distributed manufacturing network with our AlphaDirect™ technology. Bringing Philippe and Daniel to the ARTBIO team also deepens our manufacturing expertise to ensure efficient manufacturing and seamless delivery of our novel Pb212 alpha radioligand therapies to patients.”
- Emanuele Ostuni, Ph.D., CEO of ARTBIO
“The foundational work conducted by the stellar team of experts at ARTBIO has established the potential of alpha radioligand therapies and gives us great confidence that this team can revolutionize today’s cancer treatment paradigm. As ARTBIO is in a rapid scale-up phase, we are looking forward to supporting its growth by leveraging our deep expertise in discovery, development and operations.”
- Jeff Tong, Partner at Third Rock Ventures
“I am excited to join this talented and passionate team to help build the next wave of innovation in radiopharmaceuticals by pushing the boundaries of the platform and creating a new manufacturing paradigm that leverages my past experiences and adapts to the demands of short-lived alpha emitters.”
- Dasse
“The strong Series A funding is a clear sign of the differentiated value proposition and potential of the ARTBIO platform and a recognition of the fast progress that the team has made. We are grateful to attract such high-quality investors and associated board members whose deep experience in drug discovery and development as well as company building will serve us well as we continue driving our novel pipeline forward.”
- Ted Love, M.D., ARTBIO Board Chairman and Biotechnology Innovation Organization’s (BIO) Board Chairman
